Tiny study tracks heart Drug's journey in healthy men

NCT ID NCT07656779

Not yet recruiting Knowledge-focused Sponsor: Shandong Suncadia Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study will give a small dose of a radioactive-labeled drug called HRS-1893 to 6 healthy men. Researchers will track how the drug is absorbed, broken down, and eliminated through urine and feces. The goal is to understand the drug's path in the body, which is a key step before testing it as a treatment for heart muscle diseases.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HRS-1893 (a radioactive-labeled drug)
What this could lead to: If successful, this study will help researchers understand how HRS-1893 is processed and eliminated by the body, guiding future trials for heart muscle diseases.
What could go wrong: This is a very early Phase 1 study with only 6 healthy volunteers, not patients. It focuses on basic drug behavior, not treatment effects, so it may not lead to a therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOMYOPATHIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiomyopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIOMYOPATHIES

Contacts and locations

Locations

Jiangnan University Affiliated Hospital

Wuxi, Jiangsu, 214100, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.